We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Oct 2023 to Apr 2024
By Rob Curran
Lava Therapeutics shares surged after the biotech company said one of its product candidates would be tested on prostate-cancer patients in combination with Merck's blockbuster Keytruda drug.
The Dutch biopharmaceutical firm said the LAVA-1207 drug will be tested in combination with Keytruda on patients with therapy refractory metastatic castration-resistant prostate cancer, a particularly severe form of the disease.
Like Keytruda, Lava's suite of Gammabody drugs use an immunotherapy approach to target cancer cells. Merck will supply the Keytruda doses for patients in Lava's ongoing early-stage Phase 1/2a clinical trial of LAVA-1207, with the combination set to begin in the first half of this year.
Shares of Lava rose 32% to $2.06.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 25, 2024 07:52 ET (12:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
